🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Jon Arnason

Beth Israel Deaconess Medical Center

ORCID: 0000-0001-9038-7277
MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 5%percentile
0.518Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL

Blood Advances(2024)10.1182/bloodadvances.2023011574
Top 37%
0.518DataRank
Top 37%12 citations

Danielle M. Brander, Yue Ren, Yinglu Zhou, Svitlana Tyekucheva, Heather A. Walker +18 more

Papers

Driven by 7 papers — median percentile 63. Top paper: “Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study”.

Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study

The Lancet Oncology(2021)10.1016/s1470-2045(21)00455-1
N/A
3.3DataRank · unranked
104 citations

Benjamin L. Lampson, Svitlana Tyekucheva, Zixu Wang, Jessica Lowney, Samantha Pazienza +13 more

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL

Blood Advances(2024)10.1182/bloodadvances.2023011574
Top 37%
0.518DataRank
Top 37%12 citations

Danielle M. Brander, Yue Ren, Yinglu Zhou, Svitlana Tyekucheva, Heather A. Walker +18 more

A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia

Leukemia(2021)10.1038/s41375-021-01441-9
N/A
0.464DataRank · unranked
21 citations

Alec Griffith, Svitlana Tyekucheva, Zixu Wang, Vanessa Rai, Alexander R. Vartanov +14 more

Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia

Blood Advances(2025)10.1182/bloodadvances.2025016006
N/A
0.385DataRank · unranked
12 citations

Yinglu Zhou, Mariia Mikhaleva, Daniel Choi, Stacey M. Fernandes, Philippe Armand +20 more

Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis

Blood(2020)10.1182/blood.2020008206
N/A
0DataRank · unranked
33 citations

Adam S. Sperling, Christopher J. Gibson, Kaushik Viswanathan, Cecilia A. Castellano, Marie McConkey +16 more

Long‐term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia

HemaSphere(2025)10.1002/hem3.70067
N/A
0DataRank · unranked
0 citations

Yue Ren, Svitlana Tyekucheva, Jon Arnason, Adam Boruchov, Caron A. Jacobson +6 more

140 | PHASE 2 TRIAL OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN COMBINATION WITH ACALABRUTINIB IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMAS (LBCL)

Hematological Oncology(2025)10.1002/hon.70093_140
N/A
0DataRank · unranked
0 citations

Jon Arnason, Robert Redd, J. Erika Haydu, Jacob D. Soumerai, Jeffrey A. Barnes +7 more